After finding that immune checkpoint inhibitors (ICIs) do not work as well for patients who had taken antibiotics, the investigators suggest restoring the gut microbiome before starting therapy.
Twelve genetic mutations in clear-cell renal cell carcinoma may predict which patients will experience recurrence; they could also help personalize adjuvant treatment, researchers say.
A novel combination of high-dose abatacept, ruxolitinib, and mechanical ventilation markedly improved immunotherapy-induced myocarditis survival over current guideline-recommended treatment.
Radiolabeled 89Zr-DFO-girentuximab PET/CT can accurately and noninvasively identify clear cell renal carcinoma, with minimal toxicity, say researchers reporting results from the phase 3 ZIRCON trial.